Cargando…

Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer

Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this. For example, pembrolizumab is the recommended first‐line treatment for non‐small cell lung cancer (NSCLC) with no driver alterat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Timothy, Cao, Yanguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931430/ https://www.ncbi.nlm.nih.gov/pubmed/36547213 http://dx.doi.org/10.1002/psp4.12896

Ejemplares similares

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab
por: Tsui, James M, et al.
Publicado: (2018)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
por: Liu, Wenjie, et al.
Publicado: (2023)

Octogenarians may benefit from stage-specific small cell lung cancer treatment
por: Zhou, Bin, et al.
Publicado: (2021)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma
por: Oki, Rikako, et al.
Publicado: (2019)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021)

Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis
por: Nakahama, Kenji, et al.
Publicado: (2022)

Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer
por: Yamagata, Satoshi, et al.
Publicado: (2019)

Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
por: Jan, I-Shiow, et al.
Publicado: (2023)

Benefits of lung-protective ventilation: looking beyond the ICU
por: Gupta, Namita, et al.
Publicado: (2014)

Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series
por: Zhao, Li, et al.
Publicado: (2022)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report
por: Sato, Shoki, et al.
Publicado: (2019)

A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer
por: Cohen, Max, et al.
Publicado: (2020)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2021)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
por: Huang, Min, et al.
Publicado: (2018)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

In Translation: FcRn across the Therapeutic Spectrum
por: Qi, Timothy, et al.
Publicado: (2021)

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
por: Qi, Timothy, et al.
Publicado: (2023)

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials
por: Liu, Qiangyun, et al.
Publicado: (2021)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Beyond the Expectation: Pembrolizumab-Associated Tumor Lysis Syndrome in Metastatic Gastric Adenocarcinoma
por: Battah, Arwa, et al.
Publicado: (2023)

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies
por: Lazar, Vladimir, et al.
Publicado: (2022)

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease
por: Fujita, Tetsuo, et al.
Publicado: (2020)

Severe upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
por: Onuki, Tsugitoshi, et al.
Publicado: (2018)

Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer
por: Okawa, Sachi, et al.
Publicado: (2019)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mnpckfeat6dvtqmpggml9e0osn